FRANKFURT (Reuters) – The COVID-19 vaccine developed by Oxford University and AstraZeneca was 79% effective in a large U.S. trial at preventing symptomatic illness, and was 100% effective against severe or critical disease and hospitalisation.
(Reporting by Ludwig Burger in Frankfurt and Pushkala Aripaka in Bengaluru; Editing by Josephine Mason, Mark Potter and Sherry Jacob-Phillips)
